Trabectedin in Soft Tissue Sarcoma: Have We Hit the Bull’s-eye?

Journal of Clinical Oncology

The first phase III randomized trial of trabectedin in soft tissue sarcoma and the approval of trabectedin by the US Food and Drug Administration closely after the publication of the recent article in Journal of Clinical Oncology by Demetri et al1 add to the pre-existing metastatic soft tissue sarcoma treatment arsenal of doxorubicin, ifosfamide, gemcitabine, docetaxel, and pazopanib. However, a drug that receives a new approval must make its niche in the context of already-existing drugs and previous literature.
July 2016
50 Reads

Similar Publications